Amgen has submitted a Biologics License Application to the U.S. Food and Drug Administration for a migraine prevention medication.
The medication under review is erenumab, which is said to block migraines through the blocking of a Calcitonin Gene-Related Peptide receptor.
The study took into account 2,600 patients suffering from migraines that spanned for or more days each month, and the results were ultimately published in the April edition of The Lancet Neurology.
"People with migraine lose a substantial part of their lives enduring or managing the disease, which takes away from their loved ones, social activities and workplace responsibilities," Amgen Vice President Sean Harper said, noting that despite 3.5 million Americans taking treatments for the prevention of migraines, 80 percent are forced to stop use in a year's time.
The results from the studies concerning erenumab's effect of migraines are slated to be presented in June at the 59th Annual Scientific Meeting of the American Headache Society.
Alerts Sign-up